Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
Guidance, NICE advice and quality standards
In development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (1 active)
Skip to results
Filter by title or keyword
Filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (7)
Type
(
1 selected
)
Type
Guidance (402)
NICE advice (1)
Quality standard (10)
Guidance programme
Guidance programme
Clinical guidelines (28)
Diagnostics guidance (10)
Health technology evaluations (14)
Highly specialised technologies guidance (9)
Interventional procedures guidance (12)
Medical technologies guidance (11)
NICE guidelines (31)
Public health guidelines (1)
Technology appraisal guidance (323)
Apply filters
Showing 301 to 325 of 402
Sort by
Title
Date
Apply sorting
Type: Guidance
Remove Type: Guidance filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Pulsed Field Ablation (PFA) for atrial fibrillation
Interventional procedures guidance
12 June 2025
Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia [ID4042]
Technology appraisal guidance
16 October 2024
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]
Technology appraisal guidance
15 November 2017
Rehabilitation for chronic neurological disorders including acquired brain injury
NICE guideline
21 May 2025
Relugolix for treating hormone-sensitive prostate cancer [ID6187]
Technology appraisal guidance
14 August 2024
Relugolix–estradiol–norethisterone acetate for treating pain associated with endometriosis [ID3982]
Technology appraisal guidance
TBC
Renal cell carcinoma Pathways Pilot [ID6186]
Technology appraisal guidance
TBC
Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277]
Technology appraisal guidance
TBC
Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer TSID 12007
Technology appraisal guidance
TBC
Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307)
Technology appraisal guidance
TBC
Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]
Technology appraisal guidance
TBC
Risankizumab for previously treated moderately to severely active ulcerative colitis in people aged 16 and over ID6209
Technology appraisal guidance
TBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]
Technology appraisal guidance
TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]
Technology appraisal guidance
TBC
Robot-assisted surgery for orthopaedic procedures: early value assessment
Health technology evaluation
28 January 2025
Robot-assisted surgery for soft-tissue procedures: early value assessment
Health technology evaluation
28 January 2025
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]
Technology appraisal guidance
TBC
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]
Technology appraisal guidance
TBC
Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID5100]
Technology appraisal guidance
21 August 2024
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (Review of TA611) [ID4069]
Technology appraisal guidance
12 June 2024
Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377]
Technology appraisal guidance
29 January 2025
Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]
Technology appraisal guidance
TBC
Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998]
Technology appraisal guidance
14 August 2024
Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375]
Technology appraisal guidance
TBC
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033]
Technology appraisal guidance
TBC
Previous page
1
…
11
12
Current page
13
14
15
…
17
Page
13
of
17
Next page
Results per page
10
25
50
All
Back to top